| http://dbpedia.org/ontology/abstract
|
Remogliflozin etabonate (INN/USAN) is a dr … Remogliflozin etabonate (INN/USAN) is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by , a wholly owned subsidiary of North Carolina USA-based , and Glenmark Pharmaceuticals through a collaboration with BHV. Remogliflozin was commercially launched first in India by Glenmark in May 2019.ed first in India by Glenmark in May 2019.
|
| http://dbpedia.org/ontology/casNumber
|
442201-24-3
|
| http://dbpedia.org/ontology/chEMBL
|
494323
|
| http://dbpedia.org/ontology/fdaUniiCode
|
TR0QT6QSUL
|
| http://dbpedia.org/ontology/kegg
|
D10055
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Remogliflozin_etabonate_structure.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageID
|
18775455
|
| http://dbpedia.org/ontology/wikiPageLength
|
6810
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1109068837
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Non-alcoholic_steatohepatitis +
, http://dbpedia.org/resource/Oral_administration +
, http://dbpedia.org/resource/Category:Phenol_ethers +
, http://dbpedia.org/resource/Diabetes +
, http://dbpedia.org/resource/United_States_Adopted_Name +
, http://dbpedia.org/resource/Glenmark_Pharmaceuticals +
, http://dbpedia.org/resource/Category:SGLT2_inhibitors +
, http://dbpedia.org/resource/Gliflozin +
, http://dbpedia.org/resource/BHV_Pharma +
, http://dbpedia.org/resource/Avolynt +
, http://dbpedia.org/resource/International_Nonproprietary_Name +
, http://dbpedia.org/resource/Kissei_Pharmaceutical +
, http://dbpedia.org/resource/SGLT2 +
, http://dbpedia.org/resource/Etabonate +
, http://dbpedia.org/resource/Glycated_hemoglobin +
, http://dbpedia.org/resource/Category:Experimental_drugs +
, http://dbpedia.org/resource/Category:Glucosides +
, http://dbpedia.org/resource/Reabsorption +
, http://dbpedia.org/resource/Sodium-glucose_transport_proteins +
, http://dbpedia.org/resource/Category:Pyrazoles +
|
| http://dbpedia.org/property/atcPrefix
|
none
|
| http://dbpedia.org/property/c
|
26
|
| http://dbpedia.org/property/casNumber
|
442201
|
| http://dbpedia.org/property/chembl
|
494323
|
| http://dbpedia.org/property/chemspiderid
|
8047110
|
| http://dbpedia.org/property/h
|
38
|
| http://dbpedia.org/property/iupacName
|
5
|
| http://dbpedia.org/property/kegg
|
D10055
|
| http://dbpedia.org/property/legalStatus
|
Investigational
|
| http://dbpedia.org/property/n
|
2
|
| http://dbpedia.org/property/o
|
9
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Oral_administration +
|
| http://dbpedia.org/property/smiles
|
OC1COCOcc2Cc3cccOCC
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
UAOCLDQAQNNEAX-ABMICEGHSA-N
|
| http://dbpedia.org/property/unii
|
TR0QT6QSUL
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
401621521
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Ebicite +
, http://dbpedia.org/resource/Template:Oral_hypoglycemics +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Sodium-glucose_transporter_modulators +
, http://dbpedia.org/resource/Template:Keggcite +
, http://dbpedia.org/resource/Template:Drugbankcite +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Stdinchicite +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Pyrazoles +
, http://dbpedia.org/resource/Category:SGLT2_inhibitors +
, http://dbpedia.org/resource/Category:Glucosides +
, http://dbpedia.org/resource/Category:Experimental_drugs +
, http://dbpedia.org/resource/Category:Phenol_ethers +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Drug +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Remogliflozin_etabonate?oldid=1109068837&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Remogliflozin_etabonate_structure.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Remogliflozin_etabonate +
|
| owl:sameAs |
https://global.dbpedia.org/id/4tuP5 +
, http://rdf.freebase.com/ns/m.04gtpt3 +
, http://sh.dbpedia.org/resource/Remogliflozin_etabonat +
, http://sr.dbpedia.org/resource/Remogliflozin_etabonat +
, http://yago-knowledge.org/resource/Remogliflozin_etabonate +
, http://vi.dbpedia.org/resource/Remogliflozin_etabonate +
, http://www.wikidata.org/entity/Q7312052 +
, http://dbpedia.org/resource/Remogliflozin_etabonate +
|
| rdf:type |
http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/ontology/Drug +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/Element114840755 +
, http://dbpedia.org/class/yago/Glucoside114887801 +
, http://dbpedia.org/class/yago/WikicatGlucosides +
, http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://dbpedia.org/class/yago/WikicatPhenolEthers +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/Quintessence114847103 +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/Glycoside114887305 +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
|
| rdfs:comment |
Remogliflozin etabonate (INN/USAN) is a dr … Remogliflozin etabonate (INN/USAN) is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by , a wholly owned subsidiary of North Carolina USA-based , and Glenmark Pharmaceuticals through a collaboration with BHV. Remogliflozin was commercially launched first in India by Glenmark in May 2019.ed first in India by Glenmark in May 2019.
|
| rdfs:label |
Remogliflozin etabonate
|
